# BSF Enterprise’s Kerato partners with University of Montreal for corneal damage treatment

- Link: https://www.directorstalkinterviews.com/bsf-enterprises-kerato-partners-with-university-of-montreal-for-corneal-damage/4121171545
- Published: 2024-08-12T07:16:00+01:00
- Author: Amilia Stone

**BSF Enterprise plc** (LON:BSFA), the Main Market listed biotech company and owner
of corneal tissue replacement company Kerato Ltd, has announced that Kerato Ltd 
has entered into a Heads of Terms agreement and research partnership with the University
of Montreal in Canada.

BSF’s 100% owned Kerato is an independent company established to commercialise new
innovations in tissue engineering towards in vitro and in vivo corneal use.

As part of this strategy, Kerato will work with the University of Montreal, combining
tissue engineering expertise to further develop an in-situ gelling cornea that offers
a novel treatment for corneal damage and full thickness perforations.

Corneas are the most frequently transplanted human tissue worldwide, with around
185,000 procedures per annum^(1). However, it is estimated that 55% of the world’s
population do not have access to donor material^(1) with an estimated 12.7 million
people worldwide waiting for a transplan^(t2). The global artificial cornea and 
corneal implant market was valued at $ 421 million in 2021^(3), of which Kerato 
estimates its serviceable market to be $37.6 million.  The total market is expected
to grow at 6.9% per annum to reach $ 767.5 million by 2030^(3).

Kerato’s treatment combines host corneal stromal cells with a synthetic extracellular
matrix protein sequence to support tissue healing and re-epithelialization of the
surface of the eye.  Administered via injections to repair damaged tissue rather
than performing full transplant surgery, the treatment is expected to greatly reduce
the complexity of procedures for many patients. This is expected to reduce time 
in hospital, decrease the likelihood of graft rejection, reduce costs for health
service providers and result in better patient outcomes.

New tissue resulting from the treatment comprising the patient’s own stromal cells,
is transparent and replicates the natural curvature of the eye. Stromal cells comprise
the extracellular matrix that provide structural support for organs. Kerato’s Intellectual
property and academic partners have previously demonstrated the critical role of
corneal stromal cells in engineering a healthy extracellular matrix, and the impact
that biomechanics can have on tissue regeneration.^(3)

The partnership with the University of Montreal will build on the successful pre-
clinical studies and academic work of Professor May Griffith, advancing the translation
of the prototype corneal treatment and taking it through safety and efficacy studies,
completing clinical trials and gaining regulatory approvals before launching on 
to international markets.

To de-risk this (as well as shorten time to market) the new approach will first 
be trialled in the veterinary space giving animal owners much greater access to 
complex corneal repair treatments.

Kerato’s aim is to commercialise its advanced intellectual property in tissue engineering
and bio-engineered corneal products and accelerate progression toward clinical and
veterinary trials. Two applications are being developed, an Implantable Medical 
Device and an Ocular Toxicity Testing Platform.

> **Sarah Greenhalgh, Managing Director at Kerato Ltd said:** “This project with
> the University of Montreal marks the next step in the growth and development of
> Kerato’s corneal regenerative therapy technologies. Stromal stem cells significantly
> contribute to corneal clarity by replenishing damaged or aged keratocytes. We 
> are excited to be working on a transformative treatment for the repair of corneal
> damage which can reduce costs for healthcare providers and support improved patient
> outcomes.”

^(1)Gain P, Jullienne R, He Z, Aldossary M, Acquart S, Cognasse F, Thuret G. Global
Survey of Corneal

Transplantation and Eye Banking. JAMA Ophthalmol. 2016 Feb;134(2):167-73. doi:

10.1001/jamaophthalmol.2015.4776. PMID: 26633035

^(2)Gain P, Jullienne R, He Z, et al. Global Survey of Corneal Transplantation and
Eye Banking. JAMA Ophthalmol.

2016;134(2):167-173. doi:10.1001/jamaophthalmol.2015.4776

^(3)Artificial Cornea and Corneal Implant Market Report, 2030 (strategicmarketresearch.
com), accessed 9/04/24

^(4)Gouveia, R.M., Lepert, G., Gupta, S. et al. Assessment of corneal substrate 
biomechanics and its effect on epithelial stem cell maintenance and differentiation.
Nat Commun 10, 1496 (2019). https://doi.org/10.1038/s41467-019-09331-6

_BSF Enterprise is the parent to a portfolio of innovative subsidiary companies 
focused on developing and commercialising cell-based tissue engineering solutions
to deliver sustainable outcomes across a variety of sectors._

Share on:
